Organization (Industry)
CSA Medical, Inc. (United States)
ClinicalTrials.gov lists CSA Medical, Inc. (United States) as lead sponsor of 17 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers CSA Medical, Inc. (United States): 17 lead-sponsored trials and 1 legal-entity registration.
Disease areas (20)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Barrett Esophagus | 7 |
| Lung Neoplasms | 6 |
| Bronchitis, Chronic | 5 |
| Pulmonary Disease, Chronic Obstructive | 5 |
| Esophageal Neoplasms | 3 |
Showing 5 of 20 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2020 | 2 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 3 |
| 2009 | 3 |
| 2008 | 4 |
| 2007 | 3 |
| 2006 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 1 of 2 on time (n=2) |
Journals published in (24)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Gastrointestinal endoscopy | 4 |
| American journal of respiratory and critical care medicine | 3 |
| Endoscopy | 2 |
| Gastroenterology | 2 |
| American journal of therapeutics | 1 |
Showing 5 of 24 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 20 | 11 | 2024-07-30 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| CSA Medical truFreeze Console- Cryosurgical Unit Cryogenic Surgical Device Model: CC3-01 | Class II | 2015-03-25 |
| CSA Medical truFreeze System; Model: CC3-01, a cryogenic surgical device ***The involved units are those with the newest version of a panel PC referred to as POC-127. These panels are identified by serial number. *** The truFreeze is intended for cryogenic destruction of tissue requiring either active or passive venting during surgical procedures. The truFreeze is indicated for use as a cryosurgical tool in the fields of dermatology, gynecology, and general surgery, to ablate benign and malignant lesions. | Class II | 2014-11-10 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| CSA Medical | Lexington, US | FDA |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University System of Maryland | Co sponsors trial with | 1 |
| Reset Medical, Inc. | Co sponsors trial with | 1 |
Latest dated events (46)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-07-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-04-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-01-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-12-20 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 46 events.
Biomarker capability evidence (28)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| HGD | Trial collaborator | Named in trial inclusion criteria |
| HGD | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial collaborator | Named in trial exclusion criteria |
| ATP12A | Trial collaborator | Named in trial exclusion criteria |
| ATP12A | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 28 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.